Safety Profile of Viberzi
Viberzi, also known as eluxadoline, is a medication primarily used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. However, concerns have been raised about its safety, particularly its potential to cause serious heart problems.
Cardiovascular Risks
The most significant safety concern associated with Viberzi is the risk of myocardial infarction (heart attack) and stroke [1]. According to clinical trials and post-marketing reports [2], patients taking Viberzi have experienced cardiovascular events, including myocardial infarction and stroke, particularly with high doses.
Gastrointestinal Risks
In addition to IBS-D symptoms, Viberzi can cause gastrointestinal side effects, including abdominal pain, nausea, vomiting, and diarrhea [3]. Patients with a history of pancreatitis or those taking certain medications that affect the pancreas may be at increased risk of pancreatitis while taking Viberzi.
Other Safety Considerations
Viberzi can also cause increased liver enzymes, which may be a sign of liver damage [4]. Patients with a history of liver disease or those with certain conditions that affect liver function may need special monitoring while taking Viberzi.
Patient Monitoring
To minimize the risks associated with Viberzi, patients should be closely monitored by their healthcare providers, especially during the initial treatment period [5]. Regular assessments of cardiovascular and gastrointestinal symptoms, as well as liver enzyme levels, are essential.
Alternatives and Complementary Therapies
For patients with IBS-D who are concerned about the safety of Viberzi, alternative treatments and complementary therapies are available. These may include diet and lifestyle changes, medication such as onabotulinumtoxinA (Botox) or linaclotide (Linzess), and cognitive-behavioral therapy [6].
Conclusion
While Viberzi can be an effective treatment for IBS-D in some patients, its safety profile is a concern. Patients, particularly those with a history of cardiovascular or gastrointestinal disease, should discuss the potential risks and benefits with their healthcare provider to determine the best course of treatment. It is essential to carefully weigh the advantages and disadvantages of using Viberzi and to closely monitor treatment responses to minimize adverse effects.
Sources:
[1] https://www.drugwatch.com/medications/viberzi/side-effects/
[2] Eluxadoline - Drugs@FDA (FDA)
[3] VIBERZI (eluxadoline) Tablets, for Oral Use (Drugs.com)
[4] LiverTox: Clinical and Research Information on Drug-Induced Liver Injury
[5] Patient Information: Viberzi (eluxadoline) Tablets (Takeda Pharmaceuticals)
[6] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)